Sort   by:  
 Page size 
UnknownGantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
Not available
S-EPMC6909550 | biostudies-literature
UnknownLong-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).
Not available
S-EPMC11380290 | biostudies-literature
UnknownModelling the interplay between childhood and adult adversity in pathways to psychosis: initial evidence from the AESOP study.
Not available
S-EPMC4081841 | biostudies-literature
UnknownDevelopment and initial evaluation of a clinical prediction model for risk of treatment resistance in first-episode psychosis: Schizophrenia Prediction of Resistance to Treatment (SPIRIT).
Not available
S-EPMC11536189 | biostudies-literature
UnknownGender differences in the association between childhood physical and sexual abuse, social support and psychosis.
Not available
S-EPMC4589555 | biostudies-literature
UnknownA Novel Joint Brain Network Analysis Using Longitudinal Alzheimer's Disease Data.
Not available
S-EPMC6925181 | biostudies-literature
UnknownPrasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.
Not available
S-EPMC11031390 | biostudies-literature
UnknownSustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.
Not available
S-EPMC11645263 | biostudies-literature
UnknownHigher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer's disease.
Not available
S-EPMC8238986 | biostudies-literature
UnknownPredicting brain activity using a Bayesian spatial model.
Not available
S-EPMC4175991 | biostudies-literature
Sort   by:  
 Page size